WHAT YOU SHOULD KNOW: We are initiating coverage on six companies that we believe are undervalued players in the cell…
Read More
PSMA Program P-PSMA-101 is a solid tumor autologous CAR-T product candidate being developed to treat patients with metastatic castrate resistant…
Read More
MIAMI, June 25, 2020 /PRNewswire/ -- Rapha Capital Management, LLC (https://raphacap.com), an investment management firm located in Miami, Florida, through Rapha Capital Investment XI,…
Read More
SAN DIEGO, May 20, 2020 /PRNewswire/ -- Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to utilizing proprietary non-viral gene engineering platform technologies…
Read More
Poseida Therapeutics, Inc. Poseida Therapeutics to Present Update on Approach in Allogeneic CAR-T at Society for Immunotherapy of Cancer 34th…
Read More
SAN DIEGO, Oct. 10, 2019 /PRNewswire/ -- Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene engineering technologies to create…
Read More
SAN DIEGO, May 13, 2019 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene engineering…
Read More
MIAMI, April 22, 2019 /PRNewswire/ -- Rapha Capital Management, LLC (https://www.raphacap.com), an investment management firm located in Miami, Florida, and their associated entities…
Read More
The race to bring CAR-T cell therapy to multiple myeloma, a persistent and deadly cancer of the bone marrow, continued…
Read More
Poseida Therapeutics, Inc. Poseida Therapeutics Announces Notice of Allowance for New Patents and Registration of New Trademarks Key Patent Covers…
Read More
Is there enough enthusiasm among biotech investors to push through a $115 million-plus IPO on the latest biotech staking out…
Read More
SAN DIEGO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene engineering…
Read More
The U.S. Food and Drug Administration (FDA) has granted P-BCMA-101, Poseida Therapeutics’ CAR T-cell therapy and lead product candidate, the Regenerative Medicine Advanced Therapy (RMAT)…
Read More
Drugs which target the BCMA receptor look set to feature prominently at this year’s American Society of Haematology (ASH) meeting,…
Read More
Efficacy and safety continue to be a major advantage, with a very high response rate, no dose limiting toxicities and…
Read More
SAN DIEGO, July 20, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based clinical-stage company translating best-in-class gene…
Read More
San Diego’s Poseida Therapeutics has raised $30.5 million in venture capital funding, the cancer therapy developer said Tuesday. The Series B…
Read More